B1620

01/01/2003 - "The potential clinical use of B1620 could be expanded to malignant astrocytomas."
01/01/2003 - "B1620 inhibited anchorage-dependent growth of six astrocytoma cell lines with a median effective dose (IC50) ranging from 2.0 to 20.7 microM. "
01/01/2003 - "This study demonstrates that Ras pathway inactivation by a farnesyltransferase inhibitor, B1620, effectively inhibits in vitro and in vivo growth of human astrocytoma cells, although normal human astrocytes (NHA) derived from fetal brain are resistant to B1620. "
01/01/2003 - "All astrocytoma cells showed apoptotic figures after Hoechst 33258 staining, when treated for 5 days at each IC50 concentration against B1620. "
01/01/2003 - "Anti-proliferative effect of B1620 on in vitro growth of astrocytoma cells was examined by MTT assays and soft agar colony formation assay. "

01/01/2003 - "Daily treatment of U87 xenograft-bearing athymic mice with B1620 at 100 or 50 mg kg(-1) resulted in significant inhibition of tumor growth. "